Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M20,730Revenue $M751Net Margin (%)-20.4Altman Z-Score10.1
Enterprise Value $M20,409EPS $-0.9Operating Margin %-16.5Piotroski F-Score2
P/E(ttm)--Beneish M-Score-1.7Pre-tax Margin (%)-20.6Higher ROA y-yY
Price/Book8.710-y EBITDA Growth Rate %--Quick Ratio4.3Cash flow > EarningsN
Price/Sales24.15-y EBITDA Growth Rate %--Current Ratio5.0Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-6.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-9.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M160ROIC % (ttm)-8.0Gross Margin Increase y-yN

Gurus Latest Trades with BMRN

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
BMRNJoel Greenblatt 2015-03-31 Buy $90.28 - $129.14
($105.95)
$ 129.2922%New holding4,195
BMRNJoel Greenblatt 2014-12-31 Sold Out $67.27 - $94.19
($83.42)
$ 129.2955%Sold Out0
BMRNJoel Greenblatt 2014-09-30 Buy $55.78 - $73
($65.82)
$ 129.2996%New holding3,885
BMRNMeridian Funds 2013-06-30 Sold Out -0.09%$54.72 - $70.3
($62.32)
$ 129.29107%Sold Out0
BMRNMeridian Funds 2013-03-31 Reduce-0.17%$49.2 - $62.39
($56.51)
$ 129.29129%Reduce 69.03%40,700
BMRNMeridian Funds 2012-12-31 Reduce-0.3%$36.78 - $50.17
($45.59)
$ 129.29184%Reduce 60.99%131,400
BMRNGeorge Soros 2012-06-30 Sold Out -0.15%$32.53 - $38.87
($36.01)
$ 129.29259%Sold Out0
BMRNGeorge Soros 2012-03-31 Add0.11%$33.68 - $38.34
($32.99)
$ 129.29292%Add 300.00%300,000
BMRNGeorge Soros 2011-12-31 Reduce-0.05%$30.07 - $35.38
($32.81)
$ 129.29294%Reduce 57.14%75,000
BMRNGeorge Soros 2011-06-30 Add0.07%$24.93 - $28.455
($26.32)
$ 129.29391%Add 862.36%191,510
BMRNMeridian Funds 2011-03-31 Reduce-0.28%$23.46 - $28.29
($25.46)
$ 129.29408%Reduce 51.54%348,800
BMRNGeorge Soros 2011-03-31 Buy 0.01%$23.46 - $28.29
($25.46)
$ 129.29408%New holding19,900
BMRNGeorge Soros 2010-09-30 Sold Out -0.02%$18.24 - $23.09
($20.93)
$ 129.29518%Sold Out0
BMRNMeridian Funds 2010-03-31 Add0.13%$18.75 - $23.81
($20.92)
$ 129.29518%Add 20.83%795,900
BMRNGeorge Soros 2010-03-31 Add$18.75 - $23.81
($20.92)
$ 129.29518%Add 35.87%30,300
BMRNGeorge Soros 2009-12-31 Buy 0.01%$15.49 - $18.98
($17.17)
$ 129.29653%New holding22,300
BMRNMeridian Funds 2009-09-30 Buy 0.53%$13.86 - $18.33
($15.84)
$ 129.29716%New holding658,700
BMRNBill Gates 2009-06-30 Sold Out -0.02%$11.92 - $15.94
($13.79)
$ 129.29838%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

BMRN is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


BMRN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-05-26Sell1,625$126.553.78view
BIENAIME JEAN JACQUESCEO 2015-05-21Sell1,500$126.14.15view
SPIEGELMAN DANIEL KEVP, CFO 2015-05-18Sell2,059$124.775.26view
FUCHS HENRY JEVP, Chief Medical Officer 2015-05-18Sell1,864$124.785.25view
Davis George EricSVP, General Counsel 2015-05-18Sell2,558$125.264.85view
FUCHS HENRY JEVP, Chief Medical Officer 2015-05-13Sell1,434$121.378.21view
FUCHS HENRY JEVP, Chief Medical Officer 2015-05-11Sell2,869$121.647.97view
Ajer Jeffrey RobertSVP, Chief Commercial Of 2015-05-06Sell34,019$119.1410.23view
FUCHS HENRY JEVP, Chief Medical Officer 2015-05-01Sell414$114.5914.61view
BIENAIME JEAN JACQUESCEO 2015-05-01Sell26,723$114.9814.22view

Press Releases about BMRN :

    Quarterly/Annual Reports about BMRN:

    News about BMRN:

    Articles On GuruFocus.com
    J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
    You Can No Longer Ignore Biotech Feb 07 2014 
    Weekly Top Insider Sells: AAPL, GILD, BMRN, and PCLN Nov 19 2012 
    WEEKLY CFO SELLS HIGHLIGHT: VVUS, DIS, SNPS, TXRH, BMRN Mar 04 2012 
    5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
    Weekly CFO Sells Highlight: MSCC, BMRN, VAL, CUTR, REX, CIEN Oct 02 2011 
    BioMarin Pharmaceutical Inc. Reports Operating Results (10-K) Feb 24 2011 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 2,000 Shares Dec 13 2010 
    BioMarin Pharmaceutical Inc. (BMRN) CEO Jean Jacques Bienaime sells 1,000 Shares Dec 07 2010 

    More From Other Websites
    Analyst Has 4 Top US Growth Stock Calls for This Week May 27 2015
    Cramer shuts down this market's haters May 22 2015
    Biotech stock set to double May 21 2015
    Sarepta’s Feast May Not Satisfy May 20 2015
    Sarepta Gets FDA Green Light to Submit Application May 20 2015
    These biotech names are ripe for mergers: Analysts May 10 2015
    10-Q for BioMarin Pharmaceutical, Inc. May 07 2015
    BioMarin Pharmaceutical (BMRN): Strong Industry, Solid Earnings Estimate Revisions - Tale of the... May 07 2015
    Why These 4 Biotech Stocks Could Be the Next Buyout Targets May 07 2015
    Biotech takeover targets May 06 2015
    Why BioMarin's New Drug Application is Good News for Sarepta Therapuetics May 06 2015
    Rare disease stocks fly on Alexion acquisition May 06 2015
    Baird Upgrades Sarepta Therapeutics After Positive Signal That FDA Is Ready To Review May 06 2015
    Sure, the Biotech Sector is Getting Hammered. Here's How to Take Advantage. May 05 2015
    BIOMARIN PHARMACEUTICAL INC Files SEC form 10-Q, Quarterly Report May 05 2015
    No, the Biotech Boom Isn't Over May 04 2015
    BioMarin Q1 Loss Narrower than Expected, '15 View Revised - Analyst Blog May 01 2015
    BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th;... May 01 2015
    BioMarin Management to Present at the Deutsche Bank 40th Annual Health Care Conference on May 6th;... May 01 2015
    BioMarin Pharmaceutical (BMRN) Earnings Report: Q1 2015 Conference Call Transcript May 01 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK